2.77

0.73% 0.02

Pre-market: 2.81 0.04 +1.44%

Atai Life Sciences N V (ATAI)

Overview News Price History Option Chain Financials Discussions Forecast

Atai Life Sciences N V stock is traded at $2.77, with a volume of 4.12M. It is up +0.73% in the last 24 hours and up +17.87% over the past month. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Previous Close:

$2.75

Open:

$2.79

24h Volume:

4.12M

Relative Volume:

2.03

Market Cap:

$474.18M

Revenue:

$314.00K

Net Income/Loss:

$-40.23M

P/E Ratio:

-9.8929

EPS:

-0.28

Net Cash Flow:

$-84.71M

1W Performance:

+23.11%

1M Performance:

+17.87%

6M Performance:

+56.50%

1Y Performance:

+116.41%

1-Day Range:

$2.62

$2.80

1-Week Range:

$2.15

$2.96

52-Week Range:

$1.03

$2.96

Atai Life Sciences N V Stock (ATAI) Company Profile

Name

Atai Life Sciences N V

Sector

Healthcare (1157)

Industry

Biotechnology (651)

Phone

49 89 2153 9035

Address

WALLSTRASSE 16, BERLIN

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ATAI's Discussions on Twitter

Compare ATAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATAI Atai Life Sciences N V	2.77	474.18M	314.00K	-40.23M	-84.71M	-0.28
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Reiterated	H.C. Wainwright	Buy
Apr-03-24	Upgrade	Maxim Group	Hold → Buy
Nov-01-22	Initiated	Loop Capital	Buy
Nov-30-21	Initiated	Maxim Group	Buy
Nov-11-21	Initiated	ROTH Capital	Buy
Oct-18-21	Initiated	H.C. Wainwright	Buy
Sep-01-21	Initiated	Jefferies	Buy
Jul-13-21	Initiated	Berenberg	Buy
Jul-13-21	Initiated	Canaccord Genuity	Buy
Jul-13-21	Initiated	Cantor Fitzgerald	Buy
Jul-13-21	Initiated	Citigroup	Buy
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Credit Suisse	Outperform
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform
Jul-08-21	Initiated	Aegis Capital	Buy

View All

Atai Life Sciences N V Stock (ATAI) Latest News

Jun 18, 2025

ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus

Jun 18, 2025

Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire

Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.

Jun 15, 2025

Jun 13, 2025

ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com

Jun 13, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com

Jun 13, 2025

Jun 12, 2025

Atai Life Sciences (ATAI) Garnered a Buy Rating and $12 Target | ATAI Stock News - GuruFocus

Jun 12, 2025

Jun 09, 2025

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance

Jun 09, 2025

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jun 09, 2025

Jun 07, 2025

Lucid Capital Markets initiates coverage on atai Life Sciences stock By Investing.com - Investing.com Nigeria

Jun 07, 2025

Jun 06, 2025

ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus

Jun 06, 2025

Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com

Jun 06, 2025

Jun 05, 2025

ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire

Jun 03, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - Morningstar

Jun 03, 2025

H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India

Jun 03, 2025

H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com

Jun 03, 2025

Atai in $370M merger deal with psychedelic drug specialist Beckley - BioWorld MedTech

Jun 03, 2025

Jun 02, 2025

atai Life Sciences (ATAI) Merges with Beckley Psytech for Psyche - GuruFocus

Jun 02, 2025

atai Life Sciences and Beckley Psytech merging - Seeking Alpha

Jun 02, 2025

Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com

Jun 02, 2025

Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com

Jun 02, 2025

Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg

Jun 02, 2025

ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus

Jun 02, 2025

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance

Jun 02, 2025

ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com - Investing.com UK

Jun 02, 2025

May 30, 2025

Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine

May 30, 2025

May 29, 2025

atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo

May 29, 2025

May 27, 2025

2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com

May 27, 2025

May 24, 2025

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga

May 24, 2025

May 23, 2025